This article is part of the supplement: Proceedings of Delivery Systems and Current Strategies to Drug Design

Open Access Proceedings

Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi

Reinaldo Acevedo1*, Adriana Callicó1, Yisabel Aranguren1, Caridad Zayas1, Yolanda Valdés1, Oliver Pérez1, Luis García1, Valerie A Ferro2 and José Luis Pérez1

Author affiliations

1 Research and Development vice-presidency of Finlay Institute, Havana, Cuba

2 University of Strathclyde, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, G4 0NR, UK

For all author emails, please log on.

Citation and License

BMC Immunology 2013, 14(Suppl 1):S10  doi:10.1186/1471-2172-14-S1-S10

Published: 25 February 2013


The proteoliposome derived from Vibrio cholerae O1 (PLc) is a nanoscaled structure obtained by a detergent extraction process. Intranasal (i.n) administration of PLc was immunogenic at mucosal and systemic level vs. V. cholerae; however the adjuvant potential of this structure for non-cholera antigens has not been proven yet. The aim of this work was to evaluate the effect of coadministering PLc with the Vi polysaccharide antigen (Poli Vi) of S. Typhi by the i.n route. The results showed that Poli Vi coadministered with PLc (PLc+Poli Vi) induce a higher IgA response in saliva (p<0.01) and faeces (p<0.01) than Poli Vi administered alone. Likewise, the IgG response in sera was higher in animals immunised with PLc+Poli Vi (p<0.01). Furthermore, IgG induced in sera of mice immunised with PLc+Poli Vi was similar (p>0.05) to that induced in a group of mice immunised by the parenteral route with the Cuban anti-typhoid vaccine vax-TyVi®, although this vaccine did not induce a mucosal response. In conclusion, this work demonstrates that PLc can be used as a mucosal adjuvant to potentiate the immune response against a polysaccharide antigen like Poli Vi.